<DOC>
	<DOC>NCT02258152</DOC>
	<brief_summary>The purpose of this study placebo-controlled, randomized, double-blind study is to assess the safety and efficacy of SYN120 in patients with Parkinson's disease dementia (PDD) already treated with a stable dose of a cholinesterase inhibitor.</brief_summary>
	<brief_title>SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)</brief_title>
	<detailed_description>This study includes a Screening Period of up to 6 weeks, a 16 week Treatment Period, and a 2 week Safety Follow Up Period. Final eligibility will be determined at the Baseline Visit. Eligible patients will be randomized to receive placebo or SYN120 100 mg once a day (QD).</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Serotonin 5-HT2 Receptor Antagonists</mesh_term>
	<criteria>Parkinson's Disease Dementia Patient has a routine caregiver Taking a stable cholinesterase inhibitor. Patient has a Montreal Cognitive Assessment (MoCA) 1023 inclusive History of any significant neurologic or psychiatric disease other than PD Any other condition or clinically significant abnormal findings that would make the patient unsuitable for the study Unpredictable motor fluctuations that would interfere with administering assessments</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PDD</keyword>
	<keyword>Parkinson's Disease Dementia</keyword>
	<keyword>patients taking a cholinesterase inhibitor.</keyword>
</DOC>